Gene Therapy Roctavian Prevents Bleeds Over 5 Years, Data Show

Gene Therapy Roctavian Prevents Bleeds Over 5 Years, Data Show

295283

Gene Therapy Roctavian Prevents Bleeds Over 5 Years, Data Show

The investigational gene therapy Roctavian continues to effectively and safely prevent bleeding episodes and the need for clotting factor VIII replacement therapy in adults with severe hemophilia A, five-year data from a Phase 1/2 study show. BioMarin Pharmaceutical, the therapy’s developer, plans to share the data in an oral presentation at the upcoming International Society on Thrombosis and Haemostasis Virtual Congress, held July 17–21, in Philadelphia. “As a treating physician and the physician who dosed…

You must be logged in to read/download the full post.